A	a	O	O
phase	phase	O	O
I	i	O	O
clinical	clinical	O	O
study	study	O	O
of	of	O	O
the	the	O	O
antipurine	antipurine	O	O
antifolate	antifolate	S_chemicals	O
lometrexol	lometrexol	O	O
(	(	O	O
DDATHF	ddathf	O	O
)	)	O	O
given	given	O	O
with	with	O	O
oral	oral	O	O
folic	folic	B_chemicals	B_disease
acid	acid	S_chemicals	I_disease
.	.	O	O

Lometrexol	lometrexol	O	O
is	is	O	O
an	an	O	O
antifolate	antifolate	S_chemicals	O
which	which	O	O
inhibits	inhibits	O	O
glycinamide	glycinamide	B_chemicals	O
ribonucleotide	ribonucleotide	S_chemicals	O
formyltransferase	formyltransferase	S_chemicals	O
(	(	O	O
GARFT	garft	O	O
)	)	O	O
,	,	O	O
an	an	O	O
enzyme	enzyme	S_chemicals	O
essential	essential	O	O
for	for	O	O
de	de	O	O
novo	novo	S_chemicals	O
purine	purine	O	O
synthesis	synthesis	O	O
.	.	O	O

Extensive	extensive	O	O
experimental	experimental	O	O
and	and	O	O
limited	limited	O	O
clinical	clinical	O	O
data	data	O	O
have	have	O	O
shown	shown	O	O
that	that	O	O
lometrexol	lometrexol	O	O
has	has	O	O
activity	activity	O	O
against	against	O	O
tumours	tumours	O	O
which	which	O	O
are	are	O	O
refractory	refractory	O	O
to	to	O	O
other	other	O	O
drugs	drugs	S_chemicals	O
,	,	O	O
notably	notably	O	O
methotrexate	methotrexate	S_chemicals	O
.	.	O	O

However	however	O	O
,	,	O	O
the	the	O	O
initial	initial	O	O
clinical	clinical	O	O
development	development	O	O
of	of	O	O
lometrexol	lometrexol	O	O
was	was	O	O
curtailed	curtailed	O	O
because	because	O	O
of	of	O	O
severe	severe	O	O
and	and	O	O
cumulative	cumulative	O	O
antiproliferative	antiproliferative	O	O
toxicities	toxicities	O	O
.	.	O	O

Preclinical	preclinical	O	O
murine	murine	O	O
studies	studies	O	O
demonstrated	demonstrated	O	O
that	that	O	O
the	the	O	O
toxicity	toxicity	O	O
of	of	O	O
lometrexol	lometrexol	O	O
can	can	O	O
be	be	O	O
prevented	prevented	O	O
by	by	O	O
low	low	B_chemicals	O
dose	dose	I_chemicals	O
folic	folic	B_chemicals	B_disease
acid	acid	S_chemicals	I_disease
administration	administration	O	O
,	,	O	O
i.e.	i.e.	O	O
for	for	O	O
7	7	O	O
days	days	O	O
prior	prior	O	O
to	to	O	O
and	and	O	O
7	7	O	O
days	days	O	O
following	following	O	O
a	a	O	O
single	single	O	O
bolus	bolus	O	O
dose	dose	O	O
.	.	O	O

This	this	O	O
observation	observation	O	O
prompted	prompted	O	O
a	a	O	O
Phase	phase	O	O
I	i	O	O
clinical	clinical	O	O
study	study	O	O
of	of	O	O
lometrexol	lometrexol	O	O
given	given	O	O
with	with	O	O
folic	folic	B_chemicals	B_disease
acid	acid	S_chemicals	I_disease
supplementation	supplementation	O	O
which	which	O	O
has	has	O	O
confirmed	confirmed	O	O
that	that	O	O
the	the	O	O
toxicity	toxicity	O	O
of	of	O	O
lometrexol	lometrexol	O	O
can	can	O	O
be	be	O	O
markedly	markedly	O	O
reduced	reduced	O	O
by	by	O	O
folic	folic	B_chemicals	B_disease
acid	acid	S_chemicals	I_disease
supplementation	supplementation	O	O
.	.	O	O

Thrombocytopenia	thrombocytopenia	O	S_disease
and	and	O	O
mucositis	mucositis	O	S_disease
were	were	O	O
the	the	O	O
major	major	O	O
toxicities	toxicities	O	O
.	.	O	O

There	there	O	O
was	was	O	O
no	no	O	O
clear	clear	O	O
relationship	relationship	O	O
between	between	O	O
clinical	clinical	O	O
toxicity	toxicity	O	O
and	and	O	O
the	the	O	O
extent	extent	O	O
of	of	O	O
plasma	plasma	O	O
folate	folate	O	O
elevation	elevation	O	O
.	.	O	O

Associated	associated	O	O
studies	studies	O	O
demonstrated	demonstrated	O	O
that	that	O	O
lometrexol	lometrexol	O	O
plasma	plasma	O	O
pharmacokinetics	pharmacokinetics	O	O
were	were	O	O
not	not	O	O
altered	altered	O	O
by	by	O	O
folic	folic	B_chemicals	B_disease
acid	acid	S_chemicals	I_disease
administration	administration	O	O
indicating	indicating	O	O
that	that	O	O
supplementation	supplementation	O	O
is	is	O	O
unlikely	unlikely	O	O
to	to	O	O
reduce	reduce	O	O
toxicity	toxicity	O	O
by	by	O	O
enhancing	enhancing	O	O
lometrexol	lometrexol	O	O
plasma	plasma	O	O
clearance	clearance	O	O
.	.	O	O

The	the	O	O
work	work	O	O
described	described	O	O
in	in	O	O
this	this	O	O
report	report	O	O
has	has	O	O
identified	identified	O	O
for	for	O	O
the	the	O	O
first	first	O	O
time	time	O	O
a	a	O	O
clinically	clinically	O	O
acceptable	acceptable	O	O
schedule	schedule	O	O
for	for	O	O
the	the	O	O
administration	administration	O	O
of	of	O	O
a	a	O	O
GARFT	garft	O	O
inhibitor	inhibitor	O	O
.	.	O	O

This	this	O	O
information	information	O	O
will	will	O	O
facilitate	facilitate	O	O
the	the	O	O
future	future	O	O
evaluation	evaluation	O	O
of	of	O	O
this	this	O	O
class	class	O	O
of	of	O	O
compounds	compounds	O	O
in	in	O	O
cancer	cancer	O	S_disease
therapy	therapy	O	O
.	.	O	O

